PNC-27 10mg Research Peptide

Product Overview

PNC-27 is a synthetic, chimeric research peptide containing an HDM-2-binding segment derived from residues 12–26 of the p53 tumor-suppressor protein, joined to a membrane-residency peptide sequence. It has been investigated primarily in laboratory models involving HDM-2 interactions, cancer-cell membrane biology, peptide-mediated pore formation, cellular selectivity, and mechanisms of cell necrosis.

Northwest Peptides supplies PNC-27 10mg as a premium-quality lyophilized research peptide manufactured exclusively for laboratory research purposes. Every batch undergoes analytical verification and includes a batch-specific Certificate of Analysis (COA).

Research Overview

PNC-27 has been investigated in preclinical studies examining its interaction with HDM-2 expressed on the membranes of certain experimental cancer-cell models. Published laboratory findings suggest that PNC-27 may form peptide–protein complexes associated with membrane-pore formation and loss of membrane integrity under controlled experimental conditions.

Researchers continue studying PNC-27 in relation to p53-derived peptide biology, HDM-2 binding, membrane localization, cellular selectivity, mitochondrial disruption, and peptide-induced necrotic mechanisms.

PNC-27 remains an experimental research compound. Its safety and effectiveness have not been established in humans, and it is not an FDA-approved treatment.

Quick Facts

Quality Assurance

Every batch of PNC-27 undergoes strict quality verification before release.

• ≥99% Purity Verified by HPLC
• Batch-Specific Certificate of Analysis (COA)
• Identity Verification
• Lyophilized for Long-Term Stability
• Sterile Laboratory Packaging
• Manufactured for Research Applications Only

Research Applications

Published preclinical literature has investigated PNC-27 in:

• HDM-2 binding studies
• p53-derived peptide research
• Cancer-cell membrane biology
• Membrane-pore formation
• Cellular selectivity studies
• Peptide–protein interactions
• Mitochondrial research
• Experimental cell-necrosis models

Literature Summary

PNC-27 is a 32-residue chimeric peptide containing the HDM-2-binding region of p53 linked to a membrane-residency sequence. Laboratory studies have examined its ability to associate with membrane-expressed HDM-2 in certain cancer-cell models.

Published in vitro and ex vivo research has reported membrane-pore formation, disruption of membrane integrity, release of intracellular contents, and necrotic cell death in selected experimental cell models. Other investigations have examined PNC-27 in leukemia, ovarian cancer, cervical cancer, and additional cellular research models.

These findings remain preclinical and should not be interpreted as evidence of safety or effectiveness in humans.

Related Research Peptides

Researchers investigating cellular signaling and experimental peptide biology frequently explore:

• PNC-28
• p53-Derived Peptides
• FOXO4-DRI
• LL-37
• Humanin
• ARA-290

Frequently Asked Questions

What is PNC-27?

PNC-27 is a synthetic chimeric peptide containing an HDM-2-binding segment derived from p53 and a membrane-residency sequence. It is investigated in laboratory studies involving HDM-2 interactions, cellular membranes, pore formation, and experimental cell-death mechanisms.

Is PNC-27 an approved cancer treatment?

No. PNC-27 is an experimental research compound. It is not approved by the FDA to diagnose, treat, cure, or prevent cancer or any other disease.

Who may purchase PNC-27?

Northwest Peptides supplies PNC-27 exclusively for lawful laboratory research.

How is it supplied?

Each vial contains 10mg of high-purity lyophilized PNC-27.

Does every batch include a COA?

Yes.

How should it be stored?

Store lyophilized material at approximately -20°C in a dry environment.

How quickly are orders shipped?

Orders are typically processed within one business day.

References

Representative peer-reviewed research includes:

• Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and is cytotoxic to cancer cells. Proceedings of the National Academy of Sciences. 2010.
• Sookraj KA, et al. The anti-cancer peptide PNC-27 induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology. 2010.
• Davitt K, et al. The anti-cancer peptide PNC-27 induces tumor-cell necrosis in a human leukemia cell line dependent on membrane HDM-2 expression. Annals of Clinical & Laboratory Science. 2014.
• Sarafraz-Yazdi E, et al. PNC-27, a chimeric p53-penetratin peptide, binds HDM-2, induces membrane-pore formation, and leads to cancer-cell lysis. Biomedicines. 2022.
• Krzesaj P, et al. Anti-cancer peptide PNC-27 kills cancer cells through interactions with HDM-2 and membrane-pore formation. Annals of Clinical & Laboratory Science. 2024.

Research Use Disclaimer

This product is intended strictly for lawful laboratory research purposes only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent cancer or any other disease. This product has not been evaluated or approved by the U.S. Food and Drug Administration.

Call to Action

Order premium-quality PNC-27 10mg from Northwest Peptides. Every batch is independently COA verified and HPLC tested for laboratory research.